 |
|
|
| |
RG-101 IN COMBINATION WITH 4 WEEKS OF ORAL DIRECT ACTING ANTIVIRAL THERAPY ACHIEVES HIGH VIROLOGIC RESPONSE RATES IN TREATMENT NAÏVE GENOTYPE 1 AND 4 CHRONIC HEPATITIS C PATIENTS: INTERIM RESULTS FROM A RANDOMISED, MULTI-CENTER, PHASE 2 STUDY
|
| |
| |
Reported by Jules Levin
EASL 2016 Barcelona April 14-17
Gabor Horvath* 1, George Papatheodoridis2, Milotka Fabri3, Mihaly Makara1, Paul Grint4, Michael Huang4, Jacqueline Blem4, Ed Lombardi5
1Buda Hepatology Center, Budapest, Hungary, 2University Gastroenterology Clinic, Medical School of Athens University, Athens, Greece, 3Clinic for Infective Disease, Clinical Center Vojvodina, Novi Sad, Republic of Serbia, 4Regulus Therapeutics, San Diego, 5Agility Clinical, Carlsbad, United States
|
| |
|
|
|
|
|
